<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03204032</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-104</org_study_id>
    <nct_id>NCT03204032</nct_id>
  </id_info>
  <brief_title>A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor</brief_title>
  <official_title>A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and
      safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and
      Thalidomide in subjects with Advanced Extrapancreatic Neuroendocrine Tumor
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later) up to intolerance to the toxicity or PD (up to 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later) up to intolerable toxicity or PD (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later)up to PD or death(up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DOR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later) up to PD or death(up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later)(a year later) up to PD or death (up to 24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Extrapancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>Tegafur and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegafur and Temozolomide combined with Thalidomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur</intervention_name>
    <description>Tegafur 40-60mg po bid(d1-d14);</description>
    <arm_group_label>Tegafur and Temozolomide</arm_group_label>
    <arm_group_label>Tegafur and Temozolomide combined with Thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>200mg po qd(d10-d14)</description>
    <arm_group_label>Tegafur and Temozolomide</arm_group_label>
    <arm_group_label>Tegafur and Temozolomide combined with Thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)</description>
    <arm_group_label>Tegafur and Temozolomide combined with Thalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients should participate in the study voluntarily and sign informed consent;

          2. Histopathological proven diagnosis of low and intermediate grade (G1, G2 or G3)
             advanced Extrapancreatic neuroendocrine tumor( locally advanced, unresectable or
             distant Metastatic). For gastroenteropancreatic neuroendocrine tumor（GEP-NET）,the

             - Page 4 of 5 [DRAFT] - classification is based on nuclear mitotic number and the
             Ki-67 index,which are as follows:G1:Nuclear mitotic number &lt;2/10HPF,Ki-67
             proliferative index ≤2%.G2: Nuclear mitotic number 2～20/10HPF,Ki-67 proliferative
             index 3%～20%.G3 Nuclear mitotic number ＞ 20/10HPF,Ki-67 proliferative index ＞20%;

          3. Patients with advanced Extrapancreatic neuroendocrine tumor who had not been treated
             or had no more than two kinds of Systemic Anti-tumor Therapy,which could be
             somatostatin analogs, interferon, PRRT (peptide receptor radionuclide therapy), mTOR
             inhibitors, or chemotherapy (without any use of azole amines, fluorouracil,or
             thalidomide chemotherapy drugs);

          4. Radiological documentation of tumor progression is required within 12months prior to
             randomization;

          5. At least one measurable lesion (byRECIST1.1);

          6. ANC≥1.5×109/L,PLT≥100×109/L,HB≥90g/L,TBIL≤1.5ULN ;Without supportive care, ALT≤2.5ULN
             and ALP≤2.5ULN (without hepatic metastasis) ALT≤5ULN and ALP≤5ULN(with hepatic
             metastasis);serum creatin ≤1.5ULN and creatinine clearance rate

             ≥60ml/min；INR≤1.5ULN and APTT ≤1.5ULN ;

          7. ECOG PS:0-1;

          8. Life expectancy of more than 12 weeks;

          9. Men/Women of childbearing potential must agree to use a highly effective contraceptive
             method (such as double barrier contraceptive method，condom, oral or injectable
             contraceptives and intrauterine device) throughout treatment and for at least 90 days
             after study completion；All female patients will be considered fertile unless she has
             undergone natural menopause, artificial menopause or sterilization (such as
             hysterectomy, bilateral adnexal resection, or radioactive ovarian irradiation etc.)

        Exclusion Criteria:

          -  1、Diagnosed with high grade (G3) neuroendocrine carcinomas, adenocarcinoma, pancreatic
             islet cell carcinoma, goblet cell carcinoid, large cell neuroendocrine carcinoma, and
             small cell carcinoma; 2、Functional NET which needs concomiant use of long-acting
             somatostatin analogues to control symptoms such as insulinoma, gastrinoma, glucagon
             tumor, somatostatin, ACTH tumor, VIP tumor, and carcinoid syndrome, Zollinger-Ellison
             syndrome or other disease-specific active symptoms.

             3、Have received anti-vascular endothelial growth factor（VEGF）/VEGFR targeted drugs and
             progressed upon these drugs 4、Urinalysis shows urine protein ≥ 2+ or 24-hour protein
             quantity test shows urinary protein ≥1 g; 5、Serum potassium, calcium (albumin-bound
             ionic or corrected) or magnesium exceed the normal range with clinical significance；
             6、Under anti-hypertension treatment, still uncontrolled hypertension, defined as:
             systolic blood pressure &gt;140 mmHg or diastolic blood pressure &gt;90 mmHg;
             7、Gastrointestinal disease or condition that investigators suspect may affect drug
             absorption, including, but not limited to, active gastric and duodenal ulcers,
             ulcerative colitis and other digestive disease, gastrointestinal tumor with active
             bleeding, or other gastrointestinal conditions that may cause bleeding or perforation
             by investigator's discretion; 8、History or presence of a serious hemorrhage (&gt;30 ml
             within 3 months), hemoptysis (&gt;5 ml blood within 4 weeks) or a thromboembolic event
             (including transient ischemic attack) within 12 months; 9、Clinically significant
             cardiovascular disease, including but not limited to, acute myocardial infarction
             within 6 months prior to enrollment, severe/unstable angina pectoris or coronary
             artery bypass grafting, congestive heart failure according to the New York Heart
             Association (NYHA) classification ≥ 2; ventricular arrhythmias which needs drug
             treatment; LVEF (LVEF) &lt;50%; 10、Mean corrected QT interval (QTc) ≥ 480 msec; 11、Other
             malignancies diagnosed within the previous 5 years, except basal cell carcinoma or
             cervical carcinoma in situ after radical resection; 12、Anti-tumor therapy received
             within 4 weeks prior to the initiation of the investigational treatment, including,
             but not limited to, chemotherapy, radical radiotherapy, targeted therapy,
             immunotherapy and anti-tumor Chinese medicine treatment, hepatic chemoembolization,
             cryoablation and radiofrequency ablation ; 13、Palliative radiotherapy for a bone
             metastasis lesion within 2 weeks prior to the initiation of the investigational
             treatment; 14、Any clinically significant active infection, including, but not limited
             to, human immunodeficiency virus (HIV) infection; 15、History of clinically significant
             hepatic disease, including, but not limited to, known hepatitis B virus (HBV)
             infection with HBV DNA positive (copies ≥1×104/ml); known Hepatitis C virus （HCV)
             infection with HCV RNA positive (copies ≥1×103/m); or liver cirrhosis, etc.

             16、Surgery (except biopsy) within 28 days prior to the initiation of investigational
             treatment or unhealed surgical incision; 17、Brain metastases and/or spinal cord
             compression not treated by surgery and/or radiotherapy, and with no clinical imaging
             evidence of disease stability; 18、Toxicity from a previous anti-tumor treatment that
             does not return to Grade 0 or 1 (except for hair loss);

             19、Received investigational treatments in other clinical studies within 4 weeks prior
             to enrollment; 20、Women who are pregnant or lactating; 21、Other disease, metabolic
             disorder, physical examination anomaly, abnormal laboratory result, or any other
             conditions are inappropriate for the use of the investigational product or affect
             interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Yihebali Chi, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yihebali Chi, doctor</last_name>
    <email>dryihebalichi@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Zhao, doctor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yihebali Chi, doctor</last_name>
      <email>yihebalichi@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>yihebali chi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Tegafur</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Extrapancreatic Neuroendocrine Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

